Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 11, 2025American Journal of Hematology

European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSueh‐li LimMEMonika EngelhardtETEvangelos Terpos

Discussion

Loading...

Member takes

Overview

Consensus statement defines functional high-risk multiple myeloma and emphasizes novel induction therapy's role in predicting overall survival.

Key Points

  • Functional high-risk multiple myeloma is identified by disease progression within 18 months of therapy initiation, indicating poor prognosis.
  • About 20% of newly diagnosed multiple myeloma patients progress to functional high-risk status despite standard treatment, increasing mortality risk.
  • Current risk-stratification models lack sufficient definition of response duration to novel induction therapies, missing dynamic disease markers.
  • Improving outcomes for functional high-risk multiple myeloma hinges on understanding underlying disease biology and response to therapy.

Cite This Study

Lim et al. (2025) studied this question.

synapsesocial.com/papers/68d413ff713b0b5dfea6207chttps://doi.org/10.1002/ajh.70070
View Full Paper
Ask AI
Bookmark
Share